PPARA and breast cancer: Among fat and triglyceride lowering drugs, clofibrate, fenofibrate and WY14643 (a 2-aryl-thioacetic acid analog of clofibrate), PPAR-α agonists, present high chemosensitivity toward breast cancer cells.